KAREN LEASOR: Open Payments
NPI 1326391913 · NEW HAVEN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,430 in 75 payments from 16 companies in 2025. Trend: 2023 $1,247 · 2024 $1,390 · 2025 $1,430
Food & beverage: $1,430
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. | 23 | $418 |
| GENZYME CORPORATION | 12 | $216 |
| AstraZeneca Pharmaceuticals LP | 6 | $166 |
| Viatris Specialty LLC | 11 | $158 |
| GlaxoSmithKline, LLC. | 4 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $84 |
| Grifols USA, LLC | 2 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| Amgen Inc. | 2 | $34 |
Products named: Arikayce, DUPIXENT, YUPELRI, BREZTRI, NUCALA, UPTRAVI, Prolastin-C Liquid, TEZSPIRE.
Industry payments across KY — which companies pay providers there.
